Report

Economist Impact Study: Building Business Value in the Pharmaceutical Industry

Economist Impact Study: Building Business Value in the Pharmaceutical Industry

Prepare for a resilient future

Dataminr commissioned Economist Impact to examine global businesses’ value creation
and resilience priorities via a survey of 600 executives across six industries. In this industry profile, we take a closer look at survey findings from respondents in the pharmaceutical industry.

Read the profile  to learn how pharmaceutical companies are: 

  • Preparing for new challenges arising from geopolitical tensions
  • Innovating through the use of technologies such as AI
  • Finding a balance between physical and digital asset protection

71%
of pharma companies believe AI will have a positive impact on their ability to thrive in the next three years.

Get the report